左乙拉西坦对癫痫中老年患者骨密度及骨代谢的影响

Effect of Levetiracetam on bone mineral density and bone metabolism in the middle-aged and the elderly patients with epilepsy

目的:探讨左乙拉西坦对癫痫中老年患者骨密度及骨代谢的影响。方法:以2015年3月至2017年3月收治的癫痫患者74例为研究对象,将其随机分为观察组(37例)和对照组(37例),对照组患者给予常规抗癫痫治疗,观察组患者采用左乙拉西坦治疗,比较两组患者治疗后疗效、骨密度及骨代谢情况。结果:观察组患者骨代谢和骨密度与治疗前比较,差异无统计学意义(P>0.05);对照组与治疗前比较,血磷、血钙水平下降(P<0.05),甲状旁腺素和碱性磷酸酶升高(P<0.05),骨密度指标下降(P<0.05)。观察组患者治疗总有效率与对照组比较,差异无统计学意义(χ2=0.96,P=0.327)。结论:左乙拉西坦治疗癫痫中老年患者,临床疗效确切,且短期内不会对患者骨代谢及骨密度产生不良影响,安全可靠。

Objective： To investigate the effect of levetiracetam on bone mineral density and bone metabolism in the middle-aged and the elderly patients with epilepsy. Methods： A total of 74 patients with epilepsy hospitalized from March 2015 to March 2017 were chosen as the study subjects and randomly divided into the observation group （37 cases） and the control group （37 cases）.The patients in the control group were treated with conventional antiepileptic treatment while the patients in the observation group were treated with levetiracetam, with clinical efficacy, the bone mineral density and bone metabolism compared. Results： There was no significant change in bone metabolism and bone density indexes in the observation group, which was not statistically significant （ P 〉 0.05）. In the control group, the blood phosphorus, serum calcium levels were significantly decreased （ P 〈0.05）; the parathyroid hormone and the alkaline phosphatase were increased significantly （ P 〈0.05）; the index of bone mineral density were decreased significantly （ P 〈0.05）. There was no difference in the total effective rate between the observation group and the control group （ P 〉0.05）. Conclusion： Levetiracetam is effective in treating the middle-aged and the elderly patients with epilepsy, and there is no obvious adverse effect on bone mineral density and bone metabolism in patients in the short term, which is safe and reliable.